[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"airway-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:airway-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,71,103,132,162,184,204,231,258,285,311,338],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100527185","study-of-inflammatory-and-physiological-profiles-of-healthy-and-diseased-lung-100527185",false,"NCT06144476","Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung","RETAIN","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Aged 18 years or above\n* Patient: known or suspected airway disease\n* Healthy volunteer: considered to be in good health with no significant comorbidity (immune disorder, cancer etc.)\n\nExclusion Criteria:\n\n* Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.\n* Surgery within the preceding 6 weeks\n* Participants who are pregnant\n* History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection\n* Alcohol or recreational drug abuse\n* Diagnosis of immunodeficiency requiring treatment\n* Unable to provide written informed consent\n* Unable to read or write English\n* Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study",true,"ALL","18 Years",{"count":20,"type":21},230,"ESTIMATED","OBSERVATIONAL","There are over 700,000 UK hospital admissions every year with lung disease symptoms. Two of the most common lung diseases contributing to these numbers are asthma and chronic obstructive pulmonary disease (COPD). The immunopathology of these diseases is not fully understood. Matched samples from the respiratory tract and circulation will be used to identify immune patterns throughout the respiratory system to elucidate the immunopathology of airway disease.",[25,26,27],"COPD","Asthma","Airway Disease",[27,29],"Pulmonary Disease","RECRUITING","2026-06-03",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2024-02-08",{"date":38,"type":21},"2029-08-31",{"name":40,"class":41},"Guy's and St Thomas' NHS Foundation Trust","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100427593","treatment-of-central-airway-stenoses-using-computer-assisted-customized-3d-stents-tatum-100427593","NCT04848025","Treatment of Central Airway Stenoses Using Computer-Assisted Customized 3d Stents TATUM","Treatment of Central Airway Stenoses Using Computer-Assisted Customized 3d Stents TATUM (Three-dimensional Airway Tailored Stent Using Computer-aided Modeling)","TATUM","Inclusion Criteria:\n\n* Age \\>18 years\n* Informed consent\n* Complex, proximal and symptomatic (dyspnea, cough, peak flow \\\u003C 50%, FEV1 \\\u003C 50% or post-stenotic infection) airway stenosis\n\nExclusion Criteria:\n\n* Acute respiratory distress, mechanical ventilation\n* Contraindication to rigid bronchoscopy (severe and irreversible coagulation disorders)\n* Pregnancy",{"count":52,"type":21},30,"INTERVENTIONAL",[55],"NA","Airway stenting is usually efficient to treat central airway obstruction but can lead to severe and potentially lethal complications (stent migration, obstructive granuloma, perforation, and hemoptysis).\n\n3D customized airway stents (computer-aided conception using CT-scan data), perfectly suited to airway anatomy, should improve the tolerance and safety of airway stenting.\n\nWe demonstrated in a previous pilot study, dedicated to patients with anatomically complex stenoses the safety of 3D patient-specific stents. These appealing results in highly complex situations suggest the need to evaluate these devices in more common situations.\n\nIn this study we aim to test our new generation stents in all patients planned for airway stenting. After computer-assisted segmentation of airways (VGStudioMAX 3.0 software), the stenosis is virtually corrected, leading to the conception of a virtual stent (AnatomikModeling, Toulouse), allowing for the fabrication of a mold using a 3D printer. The stent is then built and sterilized (NOVATECH, Berlin) and inserted during rigid bronchoscopy.\n\nClose follow up is then conducted, including clinical evaluation after one week, three, six and 12 months; spirometry at one week, 3 months, 6 months and 12 months and chest CT-scan at one week.",[27],[59,60,61],"rigid bronchoscopy","3D computer-assisted fabrication","silicon-dedicated stent","2026-05-28",{"date":64,"type":34},"2026-06-01",{"date":66,"type":34},"2021-06-17",{"date":68,"type":21},"2029-12-30",{"name":70,"class":41},"University Hospital, Toulouse",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":53,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":42},"100554740","phase-3-the-effect-of-phosphocreatine-on-medical-emergency-team-met-treated-patients-100554740","NCT06503016","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients: a Randomized Clinical Trial Protocol","SPHERE","Inclusion Criteria:\n\n1. Admitted in hospital (but outside ICU)\n2. Age\\>=18 years\n3. Written informed consent\n4. Serum creatinine \\\u003C=2 mg\u002Fdl\n5. Patient with impending or underlying cardiac failure or cardiac arrest, irrespectively of the primitive organ failure, and the Medical Emergency Team (MET) is called upon at least one of the following:\n\n   1. Threatened airways;\n   2. Respiratory arrest;\n   3. Respiratory rate \\\u003C5 or \\>36 breaths per min;\n   4. Pulse rate \\\u003C40 or \\>140 beats per min;\n   5. Systolic blood pressure \\\u003C 90 mm Hg;\n   6. Sudden fall in level of consciousness;\n   7. Fall in Glasgow coma scale of \\> 2 points.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years;\n2. Ongoing cardiac massage;\n3. Current hospital admission from a care nursing facility;\n4. Planned discharge to a care nursing facility;\n5. Reasons for withdrawal of life-sustaining therapy;\n6. History of kidney transplantation;\n7. Solitary kidney (by any reason);\n8. Serum Creatinine \\> 2 mg\u002Fdl;\n9. Immediate need for ICU admission;\n10. Known allergy to PCr;\n11. Pregnancy;\n12. Previous enrollment and randomization into this trial;\n13. Administration of PCr in the previous 30 day.",{"count":80,"type":21},400,[82],"PHASE3","Unexpected deaths and unplanned intensive care unit (ICU) admissions are common during hospital stay and are often preceded by warning abnormalities in patients' vital signs. These abnormalities trigger Medical Emergency Team (MET) activation and up to 15% of patients visited by the MET is admitted to the ICU with an overall hospital stay after the MET intervention of approximately 2 weeks. Phosphocreatine (PCr) is a natural energy-buffering molecule associated with signals of mortality reduction in patients with acute cardiac conditions (according to meta-analytic finding from our group) and with encouraging beneficial effects on other acute organ failures (e.g. brain). The investigators designed a multi-center, randomized, placebo-controlled trial to confirm the promising beneficial effects of PCr in hospitalized patients. The investigators expects a reduction in hospital stay (measured as an increase in days alive and out of hospital at 30 days) when PCr is added to standard treatment in patients requiring MET intervention.",[85,86,27,87,88,89,90,91,92,93],"Hypotension","Consciousness, Level Altered","Respiratory Failure","Tachypnea","Bradypnea","Tachycardia","Bradycardia","Cardiac Failure","Cardiac Arrest","2025-08-05",{"date":96,"type":34},"2025-08-06",{"date":98,"type":34},"2024-10-08",{"date":100,"type":21},"2026-07",{"name":102,"class":41},"Università Vita-Salute San Raffaele",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":53,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":42},"100597982","tubeless-tracheal-and-carinal-reconstruction-100597982","NCT07065565","Tubeless Tracheal and Carinal Reconstruction","Non-intubated vs Intubated Anesthesia for Tracheal and Carinal Reconstruction","NOVA-01","Inclusion Criteria:\n\n1. Airway diseases were diagnosed by chest enhanced CT and bronchoscopy\n2. The patients with age ≥ 18 and ≤ 80 years old\n3. ASA (American Society of Anesthesiologists) stage: I-III\n4. sign the informed consent. -\n\nExclusion Criteria:\n\n1. The patients have proved history of congestive heart failure, angina without good control with medicine; ECG-proved penetrating myocardial infarction; hypertension with bad control; valvulopathy with clinical significance; arrhythmia with high risk and out of control\n2. The patients have severe systematic intercurrent disease, such as active infection or poorly controlled diabetes; coagulation disorders; hemorrhagic tendency or under treatment of thrombolysis or anticoagulant therapy\n3. Airway anatomical abnormalities due to a history of surgery\n4. Patients present with other malignancy","80 Years",{"count":113,"type":21},176,[55],"In recent year, non-intubated anesthesia had emerged as an available alternative for thoracic procedure. Whether non-intubated tracheal\u002Fcarinal reconstruction confers distinct perioperative advantages over the conventional intubated approach remains uncertain. The purpose of this study was to evaluate the safety and perioperative outcomes of non-intubated versus intubated approaches in tracheal and carinal reconstruction.",[117,27],"Tracheal Disease",[119,120,121,122],"non-intubated anesthesia","airway disease","tracheal reconstruction","carinal reconstruction","2025-07-04",{"date":125,"type":34},"2025-07-15",{"date":127,"type":34},"2025-03-26",{"date":129,"type":21},"2028-08-31",{"name":131,"class":41},"Shuben Li",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":53,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":161},"100595534","feasibility-and-safety-of-the-airway-exchange-broncholaryngoscope-aeblscope-100595534","NCT07033702","Feasibility and Safety of the Airway Exchange Broncholaryngoscope (AEBLScope)","Pilot Study Assessing the Feasibility and Safety of the Airway Exchange Broncholaryngoscope (AEBLScope) During Routine Tracheostomy Tube Exchanges","Inclusion Criteria:\n\n* Age ≥18 years\n* Chronically (\\>1 month) tracheostomy-dependent outpatients\n* Currently not requiring ventilatory or supplemental oxygen support\n* Have undergone at least one prior tracheostomy tube exchange\n* Scheduled for routine in-office tracheostomy tube exchange\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Active respiratory infection\n* Patients with airway tubes having an inner diameter less than 6.0 mm\n* Patients with preexisting pulmonary conditions, including chronic obstructive pulmonary disease (COPD), restrictive lung disease, untreated pneumonia, or acute respiratory distress syndrome (ARDS)\n* Patients who are tracheostomy-dependent but cannot be orotracheally intubated.\n* Patients unable to provide informed consent and who have no legally authorized representative.",{"count":140,"type":21},10,[55],"This pilot study evaluates the safety and feasibility of a novel airway exchange broncholaryngoscope (AEBLScope) during routine tracheostomy tube exchanges in chronically tracheostomy-dependent adult outpatients.",[144,145,27],"Tracheotomy Patients","Airway Management",[147,148,149,150,151],"tracheostomy","bronchoscope","airway exchange","feasibility","safety","NOT_YET_RECRUITING","2025-06-19",{"date":155,"type":34},"2025-06-24",{"date":157,"type":21},"2025-09",{"date":100,"type":21},{"name":160,"class":41},"University of Southern California",2,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":111,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100591964","establishment-of-diagnosis-and-classification-system-for-lung-interstitial-and-airway-diseases-liad-100591964","NCT06987266","Establishment of Diagnosis and Classification System for Lung Interstitial and Airway Diseases (LIAD)","EDCS-LIAD","Inclusion Criteria:\n\n1. age between 40-80 years old;\n2. inpatients with an admission diagnosis of COPD, Idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, patients with the following diagnoses were screened by chest CT (slice thickness ≤1.5 mm) during hospitalization and by in-hospital or prior pulmonary function;\n3. the inpatients could complete pulmonary function and chest CT examination within 1 month after discharge;\n4. among outpatients, patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, COPD with pulmonary interstitial abnormalities, idiopathic pulmonary fibrosis with airway lesions, nonspecific interstitial pneumonia with airway lesions, pulmonary fibrosis with emphysema syndrome were diagnosed through chest CT (layer thickness ≤1.5mm) and lung function;\n5. provide informed consent.\n\nExclusion Criteria:\n\n1. expected survival less than 12 months;\n2. planned lung transplantation or pneumonectomy within 12 months;\n3. pregnant or lactating women.","40 Years",{"count":171,"type":21},900,"This study focuses on both hospitalized and outpatient populations. Through a multicenter, retrospective study, it aims to comprehensively characterize:The comorbidity of interstitial lung diseases (ILD) and airway diseases;The comorbidity of ILD with other intrapulmonary diseases;The comorbidity of airway diseases with other intrapulmonary diseases;The comorbidity of ILD and airway diseases with extrapulmonary diseases.Based on these findings, the study seeks to propose classification and diagnostic criteria for ILD and airway disease comorbidities.Additionally, a multicenter, prospective, disease-specific cohort study will be conducted to observe the prognosis of patients with ILD and\u002For airway diseases, identify prognostic factors, and grade the severity of comorbid conditions based on these factors.Finally, the study will analyze the current state of interventions and the medical costs associated with ILD and airway disease comorbidities through a cost-effectiveness analysis, aiming to propose new strategies for integrated disease management.",[174,27],"Interstitial Lung Diseases (ILD)","2025-05-22",{"date":177,"type":34},"2025-05-23",{"date":179,"type":21},"2025-05-20",{"date":181,"type":21},"2028-11-30",{"name":183,"class":41},"Xiangya Hospital of Central South University",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":42},"100514317","evaluating-treatable-traits-across-the-spectrum-of-chronic-obstructive-airways-disease-100514317","NCT05976919","Evaluating Treatable Traits Across the Spectrum of Chronic Obstructive Airways Disease","Inclusion Criteria:\n\n* Prior diagnosis of airways disease in accordance with European Respiratory Society guidelines.\n* Non \u002F ex-smokers (packs recorded as cigarettes per day \u002F years smoked).\n* Male or female aged 18-65 years\n* Ability to provide written informed consent.\n* Full comprehension of spoken and written English language.\n* Cystic Fibrosis patients on triple CFTR modulators (90% cohort)\n* Cystic Fibrosis patients on no CFTR modulators\n* Healthy controls - entirely asymptomatic, no prior history of inhaler medication use and free from respiratory disease.\n\nExclusion Criteria:\n\n* Severe exacerbation requiring hospital admission or oral corticosteroids (OCS) in the past two months.\n* Absolute or relative contraindications to cardio-pulmonary exercise testing or submaximal exercise testing.\n* Absolute or relative contraindications to pulmonary function testing .\n* Absolute or relative contraindications to dual energy x-ray (DEXA) scanning (i.e., pregnancy, recent contrast media administration or subject weight).\n* Non-ambulant or musculoskeletal impairment that may affect activities of daily living or maximal exercise testing.\n* Significant cognitive impairment (i.e., unable to provide written informed consent or safely \u002F successfully perform tests).\n* Currently receiving oxygen therapy.\n* Inability to consent.\n* Burkholderia Cepacia Complex, mycobacterium tuberculosis or mycobacterium abseccus infection.\n* Lung transplantation\n* Diagnosis of cardiovascular disease.\n* Abnormal blood screening (anaemia, moderate \u002F severe renal failure etc.)","65 Years",{"count":192,"type":21},100,"Respiratory disease affects one in five people and is a leading cause of global morbidity and mortality. Chronic obstructive airways diseases encompass conditions characterised by expiratory airflow limitation, exertional dyspnoea, activity limitation and impaired quality of life. The most common conditions include chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, cystic fibrosis and primary ciliary dyskinesia. In recent years, there has been concerted effort in the scientific and respiratory medicine community to improve the diagnosis and management of chronic obstructive airways diseases using personalised or precision medicine (i.e., tailoring therapies and interventions according to specific \"treatable traits\") and identifying phenotypes or endotypes using validated biomarkers. To date, however, research in this setting has primarily focussed on people with COPD and asthma, with limited studies in other forms of chronic obstructive airways diseases. The aim of this study is therefore two-fold; first, to compare pulmonary physiology (i.e., large and small airway involvement) and extra-pulmonary manifestations across the spectrum of chronic obstructive airways, and second, to determine how disease-specific treatable traits associate with physical activity and health-related quality of life.",[27],"2025-03-25",{"date":197,"type":34},"2025-03-30",{"date":199,"type":34},"2023-10-01",{"date":201,"type":21},"2025-07-31",{"name":203,"class":41},"University of Leeds",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":53,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":161},"100581638","feno-detection-in-asthma-diagnosis-a-new-technology-approach-100581638","NCT06852911","FeNO Detection in Asthma Diagnosis: A New Technology Approach","The Diagnostic Significance of Exhaled Nitric Oxide (FeNO) With a Novel Technology in the Assessment of Bronchial Asthma","Patients:\n\nInclusion Criteria:\n\n1. Participants must be a minimum of 18 years of age, irrespective of gender;\n2. Individuals must possess a diagnosis of bronchial asthma that aligns with the international GINA 2023 diagnostic criteria;\n3. Respiratory symptoms must have been evident for at least 6 weeks;\n4. Participants should either have no history of smoking or have discontinued smoking for a period exceeding 5 years.\n\nExclusion Criteria:\n\n1. The concurrent use of additional asthma medications (such as glucocorticoids) alongside short-acting bronchodilators within the prior 4 weeks;\n2. A diagnosis of respiratory infection within the preceding 4 weeks;\n3. Conditions such as pregnancy, lactation, or menstruation;\n4. Participation in other clinical research studies;\n5. Any underlying medical or psychiatric conditions that, in the investigator's assessment, would render the individual unsuitable for participation in the study.\n\nHealthy:\n\nInclusion Criteria:\n\n1. Participants must be at least 18 years of age, with no restrictions on gender;\n2. Individuals should not have a history of allergic diseases or chronic respiratory conditions, and must not exhibit any significant abnormalities in health assessments conducted within the past year;\n3. There should be no acute illnesses or medication history within the preceding four weeks, and participants must not display any typical symptoms of respiratory infections;\n4. A history of smoking is not permitted, or individuals must have ceased smoking for a minimum of five years.\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breastfeeding, or currently experiencing menstruation;\n2. Those who have been on long-term medication;\n3. Participants involved in other clinical research studies;\n4. Any potential medical or psychological conditions that the researcher deems may render the subject unsuitable for participation in the study.",{"count":212,"type":21},170,[55],"The detection of exhaled nitric oxide (FeNO) represents a non-invasive, safe, and rapid approach for assessing endogenous nitric oxide (NO) levels within the airway. FeNO concentrations are closely associated with airway inflammation and hyperresponsiveness, and are currently recognized as biomarkers indicative of type II airway inflammation. Recent advancements in nitric oxide detection technology for both upper and lower airways, as well as for small and large airways, have provided significant insights for the diagnosis and management of conditions such as bronchial asthma, chronic cough, upper airway diseases, chronic obstructive pulmonary disease, and even rare airway disorders. Presently, FeNO measurement is frequently employed in the differential diagnosis and monitoring of airway inflammatory diseases.\n\nThe FeNO test is conducted using a FeNO test analyzer. Internationally, FeNO detection analyzers utilize three primary methodologies: chemiluminescence, laser, and electrochemical techniques. Among these, chemiluminescence is regarded as the \"gold standard\" globally. However, due to technical constraints, this methodology has not been clinically accessible within domestic settings. In China, the electrochemical FeNO analyzer is predominantly utilized, characterized by its compact size and portability. Nonetheless, this method necessitates patient cooperation during inhalation and exhalation, rendering it impractical for individuals who are unable to comply, such as children, the elderly, and severely ill patients. Consequently, FeNO detection poses significant challenges for these populations in China, representing a notable clinical gap.\n\nThe newly implemented technology employs an innovative domestic chemiluminescence FeNO analyzer, which is exclusively available in China. This analyzer, owing to its methodological advantages, is capable of obtaining FeNO detection values from patients' natural breathing patterns, facilitating rapid response and comprehensive FeNO assessment without requiring patient cooperation. This approach, referred to as the \"Tidal-breathing of FeNO\" enables the completion of FeNO assessments in patients who are unable to engage in inspiratory and expiratory maneuvers. This advancement is anticipated to enhance the diagnostic accuracy of airway inflammation in this demographic, thereby facilitating early diagnosis, precise treatment, and improved management of disease progression.",[216,27],"Bronchial Asthma",[218,219,220],"FeNO","Bronchial asthma","Tidal breathing","2025-02-25",{"date":223,"type":34},"2025-02-28",{"date":225,"type":34},"2024-09-12",{"date":227,"type":21},"2025-09-01",{"name":229,"class":230},"Novlead Inc.","INDUSTRY",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":42},"100535115","stop-bang-questionnaire-a-predictor-of-obstructive-sleep-apnea-and-difficult-maskintubation-100535115","NCT06247631","STOP-Bang Questionnaire: A Predictor of Obstructive Sleep Apnea and Difficult Mask\u002FIntubation?","Can the STOP-Bang Questionnaire Predict Obstructive Sleep Apnea and Difficult Mask\u002FIntubation in Patients Scheduled for Thoracic Surgery? Prospective Observational Study","Inclusion Criteria:\n\n* Patient undergoing thoracic surgery\n* 18-65 years old\n* ASA 1-3\n\nExclusion Criteria:\n\n* Having a history of obstructive sleep apnea syndrome,\n* Having a history of previous head and neck surgery\u002Fradiotherapy,\n* Patients who did not agree to participate in the study",{"count":239,"type":21},125,"Difficult airway management remains the leading cause of anaesthesia-related morbidity and mortality. Obstructive sleep apnea syndrome (OSAS) is a warning sign of difficult airway management. Polysomnography is the gold standard for diagnosis of this syndrome, but the STOP-BANG questionnaire is the preferred screening test. In this study, we wanted to find an answer to the question How successful is the STOP-BANG questionnaire in screening for obstructive sleep apnea syndrome (OSAS) in predicting OSAS, difficult mask and difficult intubation in patients undergoing thoracic surgery?",[242,27],"Difficult Intubation",[244,245,246,247,248],"difficult intubation","difficult mask","Obstructive Sleep Apnea Syndrome","STOP-BANG","thoracic surgery","2025-01-28",{"date":251,"type":34},"2025-01-30",{"date":253,"type":34},"2024-01-10",{"date":255,"type":21},"2026-07-10",{"name":257,"class":41},"Atatürk Chest Diseases and Chest Surgery Training and Research Hospital",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":266,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":53,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":161},"100564507","artificial-intelligence-based-voice-assessment-of-children-and-adults-respiratory-conditions-100564507","NCT06630078","Artificial Intelligence-based Voice Assessment of Children and Adults Respiratory Conditions","Artificial Intelligence-based Voice Assessment of Children and Adults With Acute and Chronic Respiratory Conditions: Diagnostic and Prognostic Role","AIRWAY-VDAP","INCLUSION CRITERIA:\n\n* Children with bronchiolitis \\\u003C24 months of age clinically characterized according to the clinical definition accepted by international literature (Ralstone);\n* Children with asthma according to most recent GINA guidance (Global Initiative for Asthma, 2022) aged 6-12 years in a phase of proper control or during acute exacerbations;\n* Adults with upper aerodigestive tract chronic or acute clinical conditions;\n* Adults with pathologic diagnosis of head and neck cancer addressed to radiotherapy with or without chemotherapy for primary treatment of the tumor.\n\nEXCLUSION CRITERIA:\n\n* Children with comorbidities including genetic disorders;\n* Children with other chronic respiratory conditions (bronchodysplasia, cystic fibrosis);\n* Children with primary immunologic diseases;\n* Children with prematurity;\n* Children with other respiratory conditions not part of the inclusion criteria (examples: pneumonia, tonsillitis);\n* Adults over 70 years old or with neurological diseases;\n* Adults with syndromic disease;\n* Adults with malformations of upper aero-digestive tract;\n* Adults with history of head and neck surgery or not able to sustain a vocalism for more than 3 sec.","12 Months","70 Years",{"count":269,"type":21},200,[55],"Acute and Chronic respiratory conditions represent a leading cause of death and morbidity in children and adults worldwide. The diagnosis of bronchiolitis and asthmatic exacerbations is based on clinical, and mostly subjective, clinical parameters with moderately accurate prognostic role. Patients undergoing neck radiotherapy need invasive assessments of larynx. A simple biomarker like Voice may facilitate the management of these conditions. Recent studies showed that VOICE may be used as a good and easy biomarker to diagnose and monitor several respiratory and non-respiratory conditions. A prospective study aimed to collected VOICE and other clinical data in adults and children with common acute and chronic respiratory conditions at high impact on healthcare systems will be performed. VOICE-omic data will be linked with clinical findings generating data integration, using artificial intelligence technology to develop a Decision Support Systems to provide the basis for non-invasive personalised early recognition, diagnosis, monitoring and prognosis of patients with these conditions.",[27,273,274,275,26],"Cancer of Head and Neck","Radiotherapy","Bronchiolitis","2024-10-17",{"date":278,"type":34},"2024-10-18",{"date":280,"type":21},"2024-11-30",{"date":282,"type":21},"2026-09-01",{"name":284,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":17,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":53,"phases":295,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":42},"100561025","early-phase-1-therapeutic-effects-of-jing-si-herbal-tea-for-copd-100561025","NCT06584786","Therapeutic Effects of Jing Si Herbal Tea for COPD","Therapeutic Effects of Jing Si Herbal Tea for Chronic Obstructive Pulmonary Disease: A Comprehensive Investigation From Clinical to Basic Research","Inclusion Criteria:\n\n* COPD patients willing to enter this study\n\nExclusion Criteria:\n\n* not COPD patients, no willing to enter this study","20 Years",{"count":294,"type":21},120,[296],"EARLY_PHASE1","Chronic obstructive pulmonary disease (COPD), a leading cause of global mortality, significantly impairs health-related quality of life (HRQL). COPD is characterized by airway inflammation and lung tissue damage. Jing Si herbal tea (JSHT) is known to have anti-inflammatory effects but has not been explored for treating COPD. This study investigated the potential of JSHT as an adjuvant therapy for COPD. This randomized controlled study focused on patients with COPD in the exacerbation and stable phases. The control group received the standard treatment, and the JSHT group received the standard treatment plus JSHT. Both groups underwent HRQL assessments, blood tests, and cellular studies involving five different groups to assess the effect of JSHT on damage-associated molecular patterns (DAMPs) and inflammatory markers.",[27],[25,300,301],"Jing Si herbal tea","damage-associated molecular patterns","2024-09-02",{"date":304,"type":34},"2024-09-05",{"date":306,"type":34},"2022-01-01",{"date":308,"type":21},"2024-12-31",{"name":310,"class":41},"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":53,"phases":321,"briefSummary":323,"conditions":324,"keywords":328,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":161},"100478228","phase-2-effects-of-blocking-tslp-on-airway-inflammation-and-the-epithelial-immune-response-to-exacerbation-triggers-in-patients-with-copd-100478228","NCT05507242","Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD","Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD A Randomized Double-blind, Placebo-controlled Trial of Tezepelumab UPSTREAM-COPD","UPSTREAM-COPD","Inclusion Criteria:\n\n* Written informed consent\n* A diagnosis of COPD (according to GOLD (GOLD 2021 Report))\n* ≥ 10 packyears smoked (current or ex-smokers)\n* Age 40 years or older\n* Postbronchodilator FEV1 ≥ 30% predicted (and ≥ 1.0L) and \\\u003C 80% predicted\n* Maintenance treatment with LAMA+LABA±ICS (stable dose) for at least 3 months prior to V1\n* ≥1 prednisolon and\u002For antibiotic treated exacerbation in the past 12 months\n* Subjects must demonstrate acceptable inhaler and spirometry techniques during screening (as evaluated and in the opinion of study site staff)\n* Subjects must demonstrate ≥ 70% compliance with daily inhalers during the screening\u002Frun-in\n* Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception from the time informed consent is obtained and must agree to continue using such precautions through Week 20 of the study; cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause).\n\nExclusion Criteria:\n\n* Previous medical history or evidence of an uncontrolled intercurrent illness that in the opinion of the investigator may compromise the safety of the subject in the study or interfere with evaluation of the investigational product or reduce the subject's ability to participate in the study. Subjects with well-controlled comorbid disease (eg, hypertension, hyperlipidemia, gastroesophageal reflux disease) on a stable treatment regimen for 15 days prior to Visit 1 are eligible.\n* Any concomitant respiratory disease that in the opinion of the investigator will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (e.g., cystic fibrosis, pulmonary fibrosis, aspergillosis, active tuberculosis).\n* Current asthma\n* Lung volume reduction surgery for COPD\n* Exacerbation requiring oral corticosteroids or antibiotics (any dose for more than 3 days) 4 weeks prior to Visit 1 or during the run-in period\n* Any use of home oxygen therapy\n* Any clinically relevant abnormal findings in hematology or clinical chemistry (laboratory results from Visit 1), physical examination, vital signs during the screening, which in the opinion of the investigator, may put the subject at risk because of his\u002Fher participation in the study, or may influence the results of the study, or the subject's ability to participate in the study\n* History of cancer: Subjects who have had basal cell carcinoma or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1. Subjects who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1.\n* Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 4 weeks prior to Visit 1 or during the screening period\n* A positive human immunodeficiency virus (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history\n* Positive hepatitis B surface antigen, or hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll.\n* History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor contraindicates their participation.\n* History of any known primary immunodeficiency disorder excluding asymptomatic selective immunoglobulin A or IgG subclass deficiency.\n* Active tuberculosis or history of untreated latent tuberculosis\n* History of anaphylaxis to any biologic therapy.\n* Use of immunosuppressive medication (eg, methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, or any experimental anti-inflammatory therapy) within 3 months prior to Visit 1.\n* Receipt of any of the following within 30 days prior to Visit 1: immunoglobulin or blood products, or receipt of any investigational nonbiologic agent within 30 days or 5 half-lives prior Visit 1, whichever is longer.\n* Receipt of any marketed or investigational biologic agent within 4 months or 5 half- lives prior to Visit 1, whichever is longer.\n* Pregnant, breastfeeding or lactating females\n* History of chronic alcohol or drug abuse within 12 months prior to Visit 1.\n* Planned surgical procedures requiring general anesthesia or in-patient status for \\> 1 day during the conduct of the study.\n* Unwillingness or inability to follow the procedures outlined in the protocol.\n* Concurrent enrollment in another clinical study involving an investigational treatment.\n* Receipt of any live or attenuated vaccines within 15 days prior to Visit 1.",{"count":320,"type":21},80,[322],"PHASE2","A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in patients with COPD.",[25,325,326,27,327],"COPD Exacerbation","COPD Bronchitis","Immune System Disorder",[25],"2024-08-19",{"date":331,"type":34},"2024-08-21",{"date":333,"type":34},"2022-10-25",{"date":335,"type":21},"2025-12-31",{"name":337,"class":41},"Asger Sverrild",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":17,"minAge":344,"maxAge":18,"enrollmentInfo":345,"targetDuration":4,"studyType":53,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":4},"100556567","bronchoscopy-versus-imaging-in-diagnosis-of-airway-diseases-in-critically-ill-children-100556567","NCT06526780","Bronchoscopy Versus Imaging in Diagnosis of Airway Diseases in Critically Ill Children","Inclusion Criteria:\n\n* Age 1 month: 18 years.\n* Critically ill patients with suspected airway diseases for the following indications:\n* Difficult intubation.\n* extubation failure (defined as the replacement of an endotracheal tube within \\\u003C48 h after extubation).\n* Persistent stridor. •Acute unexplained respiratory distress.• Localized hyperinflation.\n* Suspected foreign body.\n* Persistent and recurrent wheezes.\n* Persistent and recurrent atelectasis.\n* Unexplained hemoptysis\n\nExclusion Criteria:\n\n* Age ( \\\u003C 1month and \\> 18 years )\n* Severe hypoxemia\n* Hemodynamic instability\n* Uncorrected bleeding diathesis\n* Unresolved lung infection","1 Month",{"count":192,"type":21},[55],"Patients with suspected airway illness often go through a diagnostic assessment that includes chest radiographs, Computed tomography scans, and fiber optic bronchoscopy.",[27],"2024-07-24",{"date":351,"type":34},"2024-07-30",{"date":353,"type":21},"2024-11",{"date":355,"type":21},"2026-05",{"name":357,"class":41},"Assiut University"]